The primary objective of this study is to demonstrate the feasibility and safety of
intra-operative, intra-myocardial injection of autologous CD133 positive bone marrow cells at
the time of coronary artery bypass graft (CABG) surgery in patients with chronic ischemic
cardiomyopathy. Additionally, the feasibility of producing autologous CD133+ bone marrow stem
cells will be assessed.
The investigators hypothesize that collection of a sufficient number of CD133+ cells through
bone marrow aspiration prior to surgery, with subsequent processing and intra-myocardial
injection of high purity cells following completion of CABG, will be feasible without
significant adverse clinical consequences.